Basic Information
LncRNA/CircRNA Name | P15INK4B |
Synonyms | CDKN2B, CDK4I, INK4B, MTS2, P15, TP15, p15INK4b |
Region | NA |
Ensemble | NA |
Refseq | NA |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | ovarian cancer |
ICD-0-3 | C56.9 |
Methods | qPCR, Western blot etc. |
Sample | cell lines (SKOV3, OVCAR3, A2780, Hey, OVCA429, and OVCA433) |
Expression Pattern | down-regulated |
Function Description | we evaluated ANRIL expression in epithelial ovarian cancer (EOC) and defined its clinical implications and biological functions. ANRIL was overexpressed in EOC tissues relative to normal controls. Overexpression correlated with advanced International Federation of Gynecologists and Obstetricians stage and high histological grade. Multivariate analysis indicated that ANRIL is an independent prognostic factor for overall survival in EOC. Gain- and loss-of-function experiments demonstrated that ANRIL promotes EOC cell proliferation both in vitro and in vivo. The proliferative effect was linked to the promotion of cell cycle progression and inhibition of apoptosis and senescence. Down-regulation of P15INK4B and up-regulation of Bcl-2 by ANRIL may partially explain ANRIL-induced EOC cell proliferation |
Pubmed ID | 27095571 |
Year | 2016 |
Title | The long non-coding RNA ANRIL promotes proliferation and cell cycle progression and inhibits apoptosis and senescence in epithelial ovarian cancer |
External Links
Links for P15INK4B | GenBank HGNC NONCODE |
Links for ovarian cancer | OMIM COSMIC |